Hepatitis C drug development at a crossroads

Hepatology. 2009 Oct;50(4):997-9. doi: 10.1002/hep.23208.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Drug Therapy, Combination
  • Hepacivirus / enzymology*
  • Hepatitis C / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Oligopeptides / therapeutic use
  • Polyethylene Glycols / therapeutic use
  • Proline / analogs & derivatives
  • Proline / therapeutic use
  • Protease Inhibitors / therapeutic use*
  • Recombinant Proteins
  • Ribavirin / therapeutic use
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Oligopeptides
  • Protease Inhibitors
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline
  • peginterferon alfa-2a